Oppenheimer & Co. Inc. Has $865,000 Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Posted by Defense World Staff on Aug 27th, 2023

Oppenheimer & Co. Inc. increased its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 16.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,428 shares of the company’s stock after buying an additional 1,602 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in TransMedics Group were worth $865,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Aigen Investment Management LP acquired a new stake in shares of TransMedics Group in the 4th quarter valued at $212,000. Wealthcare Advisory Partners LLC boosted its holdings in shares of TransMedics Group by 3.7% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 5,119 shares of the company’s stock valued at $388,000 after purchasing an additional 183 shares in the last quarter. First Trust Advisors LP acquired a new stake in shares of TransMedics Group in the 4th quarter valued at $2,390,000. First Light Asset Management LLC boosted its holdings in shares of TransMedics Group by 72.4% in the 4th quarter. First Light Asset Management LLC now owns 265,097 shares of the company’s stock valued at $16,362,000 after purchasing an additional 111,328 shares in the last quarter. Finally, Jennison Associates LLC acquired a new stake in shares of TransMedics Group in the 1st quarter valued at $325,000. Institutional investors and hedge funds own 91.25% of the company’s stock.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $62.51 on Friday. The company has a quick ratio of 19.74, a current ratio of 20.70 and a debt-to-equity ratio of 3.48. TransMedics Group, Inc. has a 12-month low of $38.86 and a 12-month high of $99.63. The business has a fifty day simple moving average of $80.00 and a 200 day simple moving average of $76.41.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.12. The business had revenue of $42.46 million during the quarter, compared to analyst estimates of $42.42 million. TransMedics Group had a negative return on equity of 9.98% and a negative net margin of 11.77%. TransMedics Group’s revenue for the quarter was up 136.9% compared to the same quarter last year. During the same period last year, the company earned ($0.41) EPS. On average, equities research analysts predict that TransMedics Group, Inc. will post -0.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TMDX shares. Robert W. Baird started coverage on TransMedics Group in a report on Wednesday, July 19th. They issued an “outperform” rating on the stock. Oppenheimer increased their price target on TransMedics Group from $90.00 to $92.00 in a research note on Friday, August 4th. TheStreet upgraded TransMedics Group from a “d+” rating to a “c-” rating in a research note on Friday, August 4th. William Blair reiterated an “outperform” rating on shares of TransMedics Group in a research note on Wednesday, July 19th. Finally, TD Cowen increased their price target on TransMedics Group from $95.00 to $110.00 and gave the company an “outperform” rating in a research note on Friday, August 4th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus price target of $85.00.

Get Our Latest Analysis on TransMedics Group

Insider Buying and Selling

In other news, CEO Waleed H. Hassanein sold 7,500 shares of TransMedics Group stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $71.64, for a total value of $537,300.00. Following the completion of the transaction, the chief executive officer now directly owns 551,691 shares of the company’s stock, valued at approximately $39,523,143.24. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Waleed H. Hassanein sold 7,500 shares of TransMedics Group stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $71.64, for a total value of $537,300.00. Following the completion of the transaction, the chief executive officer now directly owns 551,691 shares of the company’s stock, valued at approximately $39,523,143.24. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 2,974 shares of TransMedics Group stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $90.05, for a total value of $267,808.70. Following the completion of the transaction, the insider now directly owns 14,375 shares of the company’s stock, valued at $1,294,468.75. The disclosure for this sale can be found here. Insiders sold a total of 30,474 shares of company stock valued at $2,598,734 in the last three months. Insiders own 6.70% of the company’s stock.

About TransMedics Group

(Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.